Novo Nordisk A/S (NOVOb.CO)
23 May 2018
Fri, May 4 2018
* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION
BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme
* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME
COPENHAGEN Novo Nordisk , the world's biggest maker of diabetes drugs, reported a smaller than expected fall in first-quarter profit and nudged up its full-year forecast as sales of new medicines helped to soften the hit from a weaker U.S. dollar.
COPENHAGEN Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast.
* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)
May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:
COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.
* OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018
* PARTICIPATES IN NEW RESEARCH PROJECT HYPO-RESOLVE TO INVESTIGATE HYPOGLYCAEMIA AND ITS IMPACT IN DIABETES
BRIEF-Emisphere Technologies Amended Its Existing 2015 Development And License Agreement With Novo Nordisk
* EMISPHERE TECHNOLOGIES INC - AMENDED ITS EXISTING 2015 DEVELOPMENT AND LICENSE AGREEMENT WITH NOVO NORDISK A/S